Metanotitia

Shenzhen, China

Metanotitia is built upon the advanced metabolomic technology that comes from MetaSysX GmbH of Germany. Metanotitia will research, develop, commercialize and market worldwide the medical applications of the innovative metabolomics technology, focusing on early diagnosis and screening of cancer. Metanotitia is well-positioned to become a world leader in medical diagnostics using metabolomics testing. MSX is a spin-off company from Max Plank Institute of Molecular Plant Physiology (MPIMP), with a mission to commercialize the metabolomics technology. MSX has been developing rapidly, in Europe and worldwide, in the business of providing metabolomics analysis services to the medical, agricultural, and food industries. MPIMP and its current Director Prof. Dr. Lothar Willmitzer pioneer the studies of metabolomics, and bio-informatics. Numerous scientific publications and IPs have been produced. They are the most influential force in the field of metabolomics. As CSO, Prof. Dr. Lothar Willmitzer will guide Company’s R&D direction — big data bioinformatics and in-vitro medical diagnostic product lines, with initial focus on the initiation of big data bioinformatic platform building and early cancer diagnoses. Beike is an established pioneer in cell therapy in China, with a hospitals and research organization network. It is developing rapidly in personalized precision medicine, which uses precision diagnostic tools and bioinformatics analyses. Beike is also very active in global partnering to develop innovative technologies in cell therapies and personalized and precision medicine.

✓Source: HealthTech Alpha by Galen Growth

Shareable draft

Check out Metanotitia on @MedStartr Today #EarlyCancerDetection #CancerOncology #Cancer #MedMo #MedStartrVentures

https://www.medstartr.ai/s/PmGi-jz55Hw

Get Involved in Metanotitia

🏢Is this your company? Claim This Profile

Join MedStartr to verify with your work email and edit this profile

Company Info

Founded: 2018
Website: metanotitia.com/

Disease Areas

Early Cancer Detection Cancer & Oncology

Technologies

MetabolomicsDiagnostic PlatformsBiotechnology

🌐Website

MedStartr Engagement Score

The MedStartr Index is a reflection of how the crowds that come to MedStartr everyday to find healthcare innovations reacted. Calculated by our AI agent Fyggy based on algorithms we have been building since 2012 and over 100 different factors, the math is proprietary and complex. Suffice to say, it has been found to be highly correlative with early stage company growth. What you see here is the public version. To learn more or to get deeper access to our predictive data on startup success for your fund or company, click here.

Comments

Comments from new members are shown once the company's team has approved them. Please follow the community rules.

Be the first to comment.

What do you think of Metanotitia?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Clinical Benefit Potential

The potential for a project to have a large and significant impact on medical care, treatment, or prevention.

Feasibility

The likelihood that this will provide benefit for patients / care givers and that the founders can execute on their vision and plan.

Innovativeness

The distinguishing features, concept, or technology that differentiates the entry compared to others that already exist and are in widespread use.

Fundability

The reviewers' beliefs that the idea is fundable or can make it to sustainability without outside investment.

Scalability

Some great ideas are destined to failure because they are too complex or too expensive. The reviewer should consider the likelihood that a project as explained, or perhaps with some tweaks, could possibly become a worldwide solution within a reasonable time frame.

Presentation Quality

How well the team presented the idea.

Submit anonymously — my name won't be shown to the team or on this profile

Your scores and comments are shown with your review on this company's profile.